Market open

Revance Therapeutics/$RVNC

14:30
22:10
05:45
13:25
21:00
1D1W1MYTD1Y5YMAX

About Revance Therapeutics

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Ticker

$RVNC
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
Nashville, United States

Employees

597
Website
www.revance.com

RVNC Metrics

BasicAdvanced
$345M
-
-$1.91
0.95
-

$345M

0.95

$7.56

$2.30

3.4M

4.119

2.902

-279.755

-296.539

-8.40%

-24.36%

225.10%

1.239

-2.12

-2.02

-1.633

25.82%

-61.84%

59.79%

-24.73%

What the Analysts think about RVNC

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Revance Therapeutics stock.

RVNC Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RVNC Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

RVNC News

AllArticlesVideos
Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming Deadline

Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire·12 hours ago
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Accesswire·17 hours ago
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

GlobeNewsWire·18 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RVNC

$

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Revance Therapeutics stock?

Revance Therapeutics (RVNC) has a market cap of $345M as of January 15, 2025.

What is the P/E ratio for Revance Therapeutics stock?

The price to earnings (P/E) ratio for Revance Therapeutics (RVNC) stock is 0 as of January 15, 2025.

Does Revance Therapeutics stock pay dividends?

No, Revance Therapeutics (RVNC) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Revance Therapeutics dividend payment date?

Revance Therapeutics (RVNC) stock does not pay dividends to its shareholders.

What is the beta indicator for Revance Therapeutics?

Revance Therapeutics (RVNC) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.